Emeis: Navigating Market Volatility with a Strategic Liquidity Agreement

Emeis, a leading healthcare and care provider, has recently published its half-year review (H2 2024) of the liquidity agreement entered into with Natixis Oddo BHF. This agreement has played a crucial role in helping emeis manage market volatility and maintain stability in its share price. In this article, we will delve into the key aspects of this liquidity agreement and its impact on emeis' financial performance.



The Liquidity Agreement: A Key Tool for Market Volatility Management

The liquidity agreement with Natixis Oddo BHF enables emeis to buy and sell its own shares, smoothing out price fluctuations and reducing the impact of market fluctuations on its share price. This agreement also provides emeis with access to a dedicated liquidity account, containing a significant amount of cash and shares. This account can be used to buy or sell shares as needed, helping to maintain stability in the share price. Additionally, the agreement allows emeis to suspend the operations provided for under the liquidity agreement during periods of financial restructuring, protecting the company from the negative effects of market volatility during these periods.



Key Takeaways from emeis' Half-Year Review

1. Increased Liquidity Account Resources: As of 31 December 2024, the liquidity account held 133,610 shares and €264,189.80 in cash. This represents a significant increase from the resources recorded as of 28 March 2024 (46 shares and €1,415,570.95 in cash) and the initial allocation on 1 December 2022 (68,000 shares and €415,650.44 in cash). This growth in liquidity account resources indicates that emeis has successfully executed its liquidity agreement, aligning with its objective to maintain a strong financial position.
2. Active Trading and Portfolio Management: During the 2024 second half-year, emeis carried out a total of 1,654 purchase transactions, acquiring 1,290,234 shares for €10,871,827.86. Additionally, emeis conducted 1,398 sale transactions, disposing of 1,270,741 shares for €10,924,037.34. These active trading activities demonstrate emeis' commitment to portfolio management and optimizing its shareholder value, which is a key strategic objective.
3. Financial Restructuring and Recovery: The liquidity agreement was suspended during emeis' financial restructuring from 1 December 2022 to 28 March 2024. The restart of the liquidity contract execution and the increase in resources allocated to it, as mentioned in the press release, indicate that emeis has successfully navigated its financial restructuring and is now focused on recovery and growth. This aligns with emeis' strategic objective to overcome challenges and rise to the major societal challenges it faces.



Conclusion

Emeis' liquidity agreement with Natixis Oddo BHF has been an invaluable tool for managing market volatility and maintaining stability in its share price. The agreement has allowed emeis to actively manage its cash flow, optimize its portfolio, and navigate financial challenges. As demonstrated by the key takeaways from emeis' half-year review, the company has successfully executed its liquidity agreement, aligning with its strategic objectives and maintaining a strong financial position. By effectively managing its liquidity agreement and engaging in active portfolio management, emeis is well-positioned to achieve its long-term goals and continue to provide high-quality healthcare and care services.